Serious Mental Illness and Tobacco Addiction: A Model Program to Address this Common but Neglected Issue

American Journal of the Medical Sciences

Volumn 326, Issue 4, 2003, Pages 223-230

  Ziedonis, Douglas ^a   Williams, Jill M ^b   Smelson, David ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Craving; Nicotine; Program development; Schizophrenia; Serious mental illness; Tobacco; Treatment

Indexed keywords

CLOZAPINE; NICOTINE; NICOTINE GUM; OLANZAPINE; RISPERIDONE;

BIPOLAR DISORDER; CONFERENCE PAPER; DISEASE ASSOCIATION; HEALTH SERVICE; HUMAN; MENTAL DISEASE; MENTAL HEALTH; QUALITY OF LIFE; SCHIZOPHRENIA; TOBACCO DEPENDENCE; UNITED STATES;

EID: 0142060063     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200310000-00014     Document Type: Conference Paper

References (50)

1. Lasser K, Wesley BJ, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-10.
2. Foulds J. The relationship between tobacco use and mental disorders. Curr Opin Psychiatry 1999;12:303-6.
3. Ziedonis DM, Kosten TR, Glazer WM, et al. Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994;45:204-6.
4. Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997;42:1-5.
5. Stuyt EB, Order-Connors B, Ziedonis DM. Addressing tobacco through program and system change in mental health and addiction settings. Psychiatr Ann 2003;33:446-56.
6. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. JAMA 1996;275:1097-103.
7. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7.
8. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502.
9. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155:1490-501.
10. Stroup TS, Gilmore JH, Jarskog LF. Management of medical illness in persons with schizophrenia. Psychiatr Ann 2000;30:35-40.
11. Goff DC, Henderson DC, Amico BS. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-94.
12. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001;15:469-94.
13. Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002;17:141-3.
14. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and of neurobiological and clinical issues. Schizophr Bull 1997;23:247-54.
15. Williams JM, Hughes JR. Pharmacotherapy treatments for tobacco dependence among smokers with mental illness or addiction. Psychiatr Ann 2003;33:457-68.
16. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-61.
17. McEvoy JP, Freudenreich O, Wilson W. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125-9.
18. George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995;56:344-6.
19. Nagamoto HT, Adler LE, McRae KA, et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999;39:10-7.
20. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-42.
21. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83.
22. Dalack GW, Meador-Woodruff JH. Smoking, smoking withdrawal, and schizophrenia: case reports and a review of the literature. Schizophr Res 1996;22:133-41.
23. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403.
24. Weiner E, Ball MP, Summerfelt A, et al. Effects of sustained-release buproprion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-7.
25. Williams JM, Ziedonis D. A pilot feasibility study of high-dose patch for patients with schizophrenia. Presented at the 9th Annual Meeting of the Society for Research on Nicotine and Tobacco; 2003 Feb 19-23; New Orleans, Louisiana. Middleton (WI): Society for Research on Nicotine and Tobacco; 2003.
26. Patten CA, Bruce BK, Hurt RD, et al. Effects of a smoke-free policy on an inpatient psychiatric unit. Tob Control 1995;4:372-9.
27. Ziedonis DM, Williams JM. Management of Smoking in People with Psychiatric Disorders. Curr Opin Psychiatry 2003;16:305-15.
28. Ziedonis DM, Trudeau K. Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. Schizophr Bull 1997;23:229-38.
29. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
30. McChargue DE, Gulliver SB, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 2002;97:785-93.
31. Jimenez-Ruiz C, Solano S, Viteri SA, et al. Harm reduction - a treatment approach for resistant smokers with tobacco-related symptoms. Respiration 2002;69:452-5.
32. Fornai E, Desideri M, Pistelli F, et al. Smoking reduction in smokers compliant to a smoking cessation trial with nicotine patch. Monaldi Arch Chest Dis 2001Feb;56:5-10.
33. Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychology 1994;62:141-6.
34. Bobo JK, MeIlvain HE, Lando HA, et al. Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial. Addiction 1998;93:877-87.
35. Clemmey P, Brooner R, Chutuape MA, et al. Smoking habits and attitudes in a methadone maintenance treatment population. Drug Alcohol Depend 1997 Mar 14;44(2-3):123-32.
36. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: Clinical Practice Guideline. Rockville (MD): Public Health Service, US Department of Health and Human Services; 2000.
37. American Psychiatric Association Practice Guideline for the Treatment of Patients with Nicotine Dependence. Am J Psychiatry 1996;153(10 Suppl):1-31.
38. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61.
39. Addington J. Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 1998;49:925-8.
40. Childress AR, Hole AV, Ehrman RN, et al. Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr 1993;137:73-95.
41. Robbins SJ, Ehrman RN, Childress AR, et al. Using cue reactivity to screen medications for cocaine abuse: a test of amantadine hydrochloride. Addict Behav 1992;17:491-9.
42. Childress AR, McLellan AT, Ehrman R, et al. Classically conditioned responses in opioid and cocaine dependence: a role in relapse? NIDA Res Monogr 1988;84:25-43.
43. Margolin A, Avants SK. Cue reactivity and cocaine addiction. In: Kosten TR, Kleber HD, editors. Clinician's guide to cocaine addiction. New York: Guilford Press; 1992. p. 109-23.
44. O'Brien CP, Childress AR, Arndt IO, et al. Pharmacological and behavioral treatments of cocaine dependence: controlled studies. J Clin Psychiatry 1988;49(suppl):17-22.
45. Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 2000;68:233-40.
46. Hutchison KE, Monti PM, Rohsenow DJ, et al. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl) 1999;142:139-43.
47. Carol, G, Smelson DA, Losonczy MF, et al Alcohol & drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiatr Serv 2001;52:1029-31.
48. Smelson DA, Losonczy MF, Kilker C, et al. An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine. Psychiatr Serv 2002;53:1612-6.
49. Substance Abuse and Mental Health Services Administration, Report to Congress on the prevention and treatment of co-occurring substance abuse disorders and mental disorders. Washington (DC): US Department of Health and Human Services; 2002. Available at: URL: http://www. samhsa.gov/reports/congress2OO2/
50. Ziedonis D, Williams J. Addressing tobacco use in mental health and addiction settings. Psychiatr Ann 2003;33:425-6.